Actively Recruiting
Mediating Role of Myokines in the Dialogue Between Muscle and Bone Tissue in a Population of Healthy Women Aged 20-89 Years
Led by Centre Hospitalier Universitaire de Nīmes · Updated on 2024-11-29
280
Participants Needed
2
Research Sites
255 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The main hypothesis is that muscle acts on bone tissue via the secretion of myokines (myostatin, follistatin, irisin). This is based on previous results showing that muscle mass in different patient populations with very different body mass indexes (anorexic or obese patients) is significantly and independently associated with bone mineral density.
CONDITIONS
Official Title
Mediating Role of Myokines in the Dialogue Between Muscle and Bone Tissue in a Population of Healthy Women Aged 20-89 Years
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Self-reported Caucasian ethnicity from Europe, Middle East, or North Africa
- Affiliated with or benefiting from a social security scheme
- Signed free and informed consent before any study examinations
You will not qualify if you...
- Fragility fracture from spontaneous or low-impact trauma
- Early menopause before age 40, hysterectomy before 40, primary amenorrhea before 15, or current amenorrhea over 3 months without contraception if under 40
- Prolonged corticosteroid therapy over 3 months or cumulative dose over 1 g
- Immobilization lasting more than 3 months within the past 12 months
- Hip fracture in a first-degree relative
- Bone, muscle, or fat tissue diseases such as inflammatory bowel disease, untreated celiac disease, renal failure on dialysis, hypercalciuria, osteomalacia, rickets, osteogenesis imperfecta, Paget's disease, osteopetrosis, chronic inflammatory rheumatism, blood disorders, cancer, liver failure or chronic hepatitis, endocrine disorders including diabetes and untreated acromegaly, anorexia nervosa, hyperparathyroidism
- History of digestive surgery except appendectomy
- History of organ transplantation
- Chronic infectious diseases like HIV
- Weight loss of more than 10 kg in the last 6 months
- Paresis, significant lameness, or prolonged immobilization over one month in the last year
- Treatments affecting bone mass or body composition such as bisphosphonates, teriparatide, denosumab, selective estrogen receptor modulators, anabolic steroids, strontium ranelate, carbamazepine, phenobarbital, immunosuppressants, or anti-epileptics
- Major deformities or previous surgeries affecting wrist, hip, or vertebrae in measurement areas
- Recent injections of radiological contrast, barium enemas, or nuclear medicine exams within 10 days
- Intensive sports activity over 10 hours per week
- Extreme body mass index below 18 or above 35 kg/m2
- Loss of autonomy or neurodegenerative disorders affecting consent ability
- Pregnant, parturient, or breastfeeding women
- Participation in an interventional drug or device study within 3 months prior to inclusion
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
C.H.R.U. Lapeyronie
Montpellier, France, 34295
Actively Recruiting
2
Chu Nimes
Nîmes, France, 30029
Actively Recruiting
Research Team
V
Vincent BOUDOUSQ, Dr
CONTACT
A
Anissa MEGZARI
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
BASIC_SCIENCE
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here